Rchr
J-GLOBAL ID：201401017332467520   Update date: Feb. 01, 2024

Shimizu Toshio

シミズ トシオ | Shimizu Toshio
Affiliation and department：
Wakayama Medical University Graduate School of Medicine Department of Respiratory Medicine and Medical Oncology

About Wakayama Medical University Graduate School of Medicine Department of Respiratory Medicine and Medical Oncology


Job title： Professor
Research field  (1)： Tumor diagnostics and therapeutics
Research keywords  (3)： 第I相試験 ,  新薬開発 ,  臨床腫瘍学
Research theme for competitive and other funds  (3)：
  • 2022 - 2025 進行癌に対する次世代抗体薬投与時サイトカインプロファイル緊急網羅的解析モデル探索
  • 2017 - 2019 <領域1-1>がんの最適医療(Precision Medicine)の実現に資するゲノム異常及びバイオマーカーの同定と臨床的有用性の検証 がん薬物療法におけるexceptional responseをもたらす遺伝子異常の研究と治療開発
  • 2012 - 2015 進行非小細胞肺癌を対象としたエルロチニブとYM155の分子標的治療薬併用第I相試験
Papers (72)：
  • Hanae Ida, Toshio Shimizu, Makoto Nishino, Yoshiaki Nakamura, Shu Yazaki, Yuki Katsuya, Jun Sato, Takafumi Koyama, Satoru Iwasa, Kazuki Sudo, et al. Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib. Cancer research communications. 2023. 3. 7. 1189-1199
  • Shigehisa Kitano, Yutaka Fujiwara, Toshio Shimizu, Satoru Iwasa, Kan Yonemori, Shunsuke Kondo, Akihiko Shimomura, Takafumi Koyama, Takahiro Ebata, Hiroki Ikezawa, et al. A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors. Cancer chemotherapy and pharmacology. 2022. 90. 6. 523-529
  • Toshio Shimizu, Kazuhiko Nakagawa, Hidetoshi Hayashi, Tsutomu Iwasa, Hisato Kawakami, Satomi Watanabe, Noboru Yamamoto, Kan Yonemori, Takafumi Koyama, Jun Sato, et al. Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study. Investigational new drugs. 2022. 41. 1. 1-12
  • Takafumi Koyama, Toshio Shimizu, Jun Sato, Yuki Katsuya, Satoru Iwasa, Shunsuke Kondo, Tatsuya Yoshida, Kazuki Sudo, Makoto Nishino, Yuichi Takiguchi, et al. Practical consideration for successful sequential tumor biopsies in first-in-human trials. Investigational new drugs. 2022. 40. 4. 841-849
  • Jun Sato, Toshio Shimizu, Takafumi Koyama, Satoru Iwasa, Akihiko Shimomura, Shunsuke Kondo, Shigehisa Kitano, Kan Yonemori, Yutaka Fujiwara, Kenji Tamura, et al. Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2022. 28. 9. 1783-1791
ｍore...
MISC (118)：
  • 武田 真幸, 中川 和彦, 林 秀敏, 岩朝 勤, 川上 尚人, 渡邉 諭美, 山本 昇, 米盛 勧, 小山 隆文, 佐藤 潤, et al. ベンダムスチン塩酸塩経口剤(SyB C-0501)の進行性固形がん患者に対する第1相臨床試験. 日本癌治療学会学術集会抄録集. 2021. 59回. O13-5
  • 清水 俊雄. アジア圏における早期新薬開発共通標準化は可能なのか?. 腫瘍内科. 2021. 27. 6. 738-742
  • 古川孝広, BARDIA Aditya, 清水俊雄, TOLCHER Anthony, SPIRA Alexander, 向原徹, LISBERG Aaron E., KROP Ian, PAPADOPOULOS Kyriakos P., HAMILTON Erika, et al. Datopotamab deruxtecanの第1相臨床試験TNBC中間結果. 日本癌治療学会学術集会(Web). 2021. 59th
  • 小山 隆文, 清水 俊雄, 米盛 勧, 小島 勇貴, 松井 直子, 大熊 ひとみ, 野口 瑛美, 須藤 一起, 平川 晃弘, 沖田 南都子, et al. MDM2阻害剤を用いた内膜肉腫対象医師主導治験. 日本心臓血管外科学会学術総会抄録集. 2020. 50回. P23-3
  • 小山 隆文, 清水 俊雄, 米盛 勧, 小島 勇貴, 松井 直子, 大熊 ひとみ, 野口 瑛美, 須藤 一起, 平川 晃弘, 沖田 南都子, et al. MDM2阻害剤を用いた内膜肉腫対象医師主導治験. 日本心臓血管外科学会学術総会抄録集. 2020. 50回. P23-3
ｍore...
Books (8)：
  • がん分子標的治療 2014年6月号(Vol.12 No.2)
    メディカルレビュー社 2014
  • 腫瘍内科 第13巻第6号(2014年6月発行)
    科学評論社 2014
  • 日本臨床 最新がん薬物療法学
    日本臨床社 2014
  • 腫瘍内科 第13巻第1号(2014年1月発行)
    科学評論社 2014
  • 腫瘍内科 第9巻第5号(2012年5月発行)
    科学評論社 2012
ｍore...
Lectures and oral presentations  (31)：
  • A first-in-Asian phase I dose escalation study to evaluate the safety and pharmacokinetics of VS-6063 (defactinib), a focal adhesion kinase inhibitor in subjects with non-hematologic malignancies
    (The 73rd Annual Meeting of the Japanese Cancer Association (JCA) 2014)
  • Phase I study of YM155, selective survivin suppressant plus elrotnib in patients with EGFR-mutant advanced non-small-cell lung cancer (NSCLC)
    (The 12th Annual Meeting of Japanese Society of Medical Oncology 2014)
  • 日本における早期探索臨床試験の推進について ~海外ベンチャー製薬企業主導型新薬第I相試験実施
    (第22回日本乳癌学会学術集会 JBCS/JSMO Joint Symposium 2014)
  • Completed Phase I Trial of TLC388
    (The 3rd Japan-Taiwan Phase I Oncology Conference (JTOPIC), Taipei, Taiwan 2014)
  • Infrastructural capability of investigator-initiated trials involving unapproved investigational drugs in Japan
    (The 11th Annual Meeting of Japanese Society of Medical Oncology 2013)
ｍore...
Education (2)：
  • 2003 - 2007 Kinki University Graduate School Medical Oncology
  • 1993 - 1999 Kinki University Faculty of Medicine Faculty of Medicine
Professional career (1)：
  • 博士(医学) (近畿大学)
Work history (8)：
  • 2022/11 - 現在 Wakayama Medical University Hospital Professor
  • 2022/04 - 現在 Wakayama Medical University Graduate School of Medicine Department of Respiratory Medicine and Medical Oncology/Cancer Center Associate Professor
  • 2016/04 - 2022/03 National Cancer Center Hospital of Japan Department of Experimental Therapeutics Head of Physician (Early Phase 1 Drug Development Service)
  • 2012/04 - 2016/03 Kindai University Faculty of Medicine Department of Medical Oncology Associate Professor
  • 2010/01 - 2012/03 START (South Texas Accelerated Research Therapeutics) Phase I Center Clinical Fellow
Show all
Committee career (4)：
  • 2022/04 - 現在 ESMO Targeted Anticancer Therapies (TAT) Scientific Committee
  • 2017/04 - 現在 The Consortium on Harmonization of Institutional Requirements for Clinical Research (CHAIR) Joint Scientific Committee Review Member for Phase 1 trials in Hong Kong, HKSAR IRB Member / Joint Scientific Committee Review Member for Phase 1 trials in Hong Kong, HKSAR
  • 2013/04 - 現在 日本臨床腫瘍学会 学術企画委員
  • 2012/04 - 現在 日本臨床腫瘍学会 評議員
Awards (2)：
  • 2019/10 - Chinese Society of Clinical Oncology (CSCO) CSCO 2019 Travel Grant Award 受賞
  • 2011/06 - ASCO ASCO 2011 Merit Award The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in first-in-human phase 1 study
Association Membership(s) (7)：
日本製薬医学会 ,  THE JAPANESE SOCIETY OF CLINICAL PHARMACOLOGY AND THERAPEUTICS ,  THE JAPAN LUNG CANCER SOCIETY ,  JSMO(日本臨床腫瘍学会) ,  THE JAPANESE SOCIETY OF INTERNAL MEDICINE ,  ASCO(American Society of Clinical Oncology) ,  AACR (American Association of Cancer Research)
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM